Pliant Therapeutics Quote - PLRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.635

Bid

1.63

Offer

1.64

Volume

2,146,368

1.6001 Day's Range 1.70

1.26 52 Week Range 16.52

Market Cap

100.121M

Previous Close

1.69

Open

1.66

Last Trade

100

1.635

Last Trade Time

06:10:33

Financial Volume

US$ 3,535,198

VWAP

1.6471

Average Volume (3m)

2,634,167

Shares Outstanding

61,236,291

Dividend Yield

PE Ratio

-0.48

Earnings Per Share (EPS)

-3.43

Revenue

Net Profit

-210.3M

Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

pliantrx.com.

Headquarters

Dover, Delaware, USA

Founded

Pliant Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PLRX. The last closing price for Pliant Therapeutics was US$1.69. Over the last year, Pliant Therapeutics shares have traded in a share price range of US$ 1.26 to US$ 16.52.

Pliant Therapeutics currently has 61,236,291 shares in issue. The market capitalisation of Pliant Therapeutics is US$103.49 million. Pliant Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date...

Form 8-K - Current report

Form 8-A12B - Registration of securities [Section 12(b)]

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO...

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX...

Form 8-K - Current report

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.045	2.83018867925	1.59	1.775	1.5	1988527	1.63995377	CS
4	-1.365	-45.5	3	3.46	1.26	3750017	1.96495756	CS
12	-11.705	-87.7436281859	13.34	14.255	1.26	2634167	3.44680149	CS
26	-11.205	-87.2663551402	12.84	16.1	1.26	1436522	5.38961557	CS
52	-12.915	-88.7628865979	14.55	16.52	1.26	941980	7.21977343	CS
156	-6.625	-80.205811138	8.26	36.64	1.26	815579	15.66256756	CS
260	-20.865	-92.7333333333	22.5	43.92	1.26	558105	16.41536534	CS

PLRX - Frequently Asked Questions (FAQ)

What is the current Pliant Therapeutics share price?

The current share price of Pliant Therapeutics is US$ 1.635

How many Pliant Therapeutics shares are in issue?

Pliant Therapeutics has 61,236,291 shares in issue

What is the market cap of Pliant Therapeutics?

The market capitalisation of Pliant Therapeutics is USD 103.49M

What is the 1 year trading range for Pliant Therapeutics share price?

Pliant Therapeutics has traded in the range of US$ 1.26 to US$ 16.52 during the past year

What is the PE ratio of Pliant Therapeutics?

The price to earnings ratio of Pliant Therapeutics is -0.48

What is the reporting currency for Pliant Therapeutics?

Pliant Therapeutics reports financial results in USD

What is the latest annual profit for Pliant Therapeutics?

The latest annual profit of Pliant Therapeutics is USD -210.3M

What is the registered address of Pliant Therapeutics?

The registered address for Pliant Therapeutics is 850 NEW BURTON ROAD SUITE 201, DOVER, DELAWARE, 19904

What is the Pliant Therapeutics website address?

The website address for Pliant Therapeutics is pliantrx.com.

Which industry sector does Pliant Therapeutics operate in?

Pliant Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
XHLDTEN Holdings Inc	US$ 1.16 (98.22%)	173.24M
LSELeishen Energy Holding Company Ltd	US$ 12.2519 (57.68%)	14.57M
BOWNBowen Acquisition Corporation	US$ 6.2642 (44.84%)	6.39M
WHLRLWheeler Real Estate Investment Trust Inc	US$ 262.87 (44.12%)	408
CSAICloudastructure Inc	US$ 7.8162 (40.33%)	3.5M
WCTWellchange Holdings Company Limited	US$ 0.2483 (-37.14%)	12.09M
ONVOOrganovo Holdings Inc	US$ 0.261 (-35.38%)	3.15M
CISOCISO Global Inc	US$ 0.5751 (-28.11%)	1.85M
KBSXFST Corporation	US$ 4.0001 (-27.14%)	4.17M
BONBon Natural Life Ltd	US$ 0.35634 (-23.58%)	27M
NVDANVIDIA Corporation	US$ 119.7999 (3.79%)	188.98M
XHLDTEN Holdings Inc	US$ 1.16 (98.22%)	173.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8.3399 (11.65%)	121.82M
SUNESUNation Energy Inc	US$ 0.4809 (22.99%)	117.69M
LCIDLucid Group Inc	US$ 2.485 (5.74%)	109.35M